9/26/2013

The National Cancer Institute has awarded BioMarker Strategies a $1.5 million grant to advance the development of its PathMap test, a companion diagnostic assay for melanoma. The company also will use the grant to finance its efforts to validate the assay in human clinical specimens.

Related Summaries